Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with GEVA as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|3.7%||ALPS Medical Breakthroughs ETF (SBIO)||N/A (N/A)|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with rare diseases. We have a pipeline of protein therapeutic programs for rare diseases with unmet medical need which are at various stages of development. We are planning for a global launch of our lead product, sebelipase alfa for lysosomal acid lipase deficiency (LAL Deficiency). Kanuma(TM) is the proposed brand name for sebelipase alfa. We have an active investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA) to evaluate our second program, SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome). We have begun dosing patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 and plan to report preliminary data from this study in the second half of 2015. ... More ...
Where does GEVA fit in the risk graph?
|Annual EPS Est:||$-5.89|
|Quarterly EPS Est:||-1.78|